Literature DB >> 20414835

Osteopontin: a biomarker to predict the outcome of inflammatory heart disease.

Karin Klingel1, Reinhard Kandolf.   

Abstract

Inflammatory processes of the heart are often induced by viruses. Although most acute virus-induced myocarditis quickly resolves, some patients develop chronic myocarditis resulting in a considerable disruption of the myocardial matrix network, finally leading to cardiac dysfunction. The death of cardiomyocytes due to virus replication is followed by the attraction of macrophages and T cells to the sites of cardiac damage. Ongoing inflammation is usually suppressed by interleukin-10 and transforming growth factor-beta production, thus activating myofibroblasts and secretion of extracellular matrix proteins like collagen type I. Also, osteopontin (OPN), a matricellular protein with cytokine-like properties, is critically involved in inflammatory pathways and can modulate the cell biology of cardiac repair. In our model of coxsackievirus B3-induced myocarditis, we have shown that increased early OPN expression in macrophages is a determinant of fibrosis and enhanced cardiac remodeling. OPN was not found to influence the efficacy of the antiviral immune response. Also, in patients with acute and chronic myocarditis, but not in patients with end-stage dilated cardiomyopathy, we found a high OPN expression in macrophages, indicating active inflammatory processes. Thus cardiac OPN expression might be considered as a biomarker indicating ongoing cardiac inflammation preceding fibrosis and remodeling of the heart. Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414835     DOI: 10.1055/s-0030-1251504

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  12 in total

1.  Effects of small platform catheter-based left ventricular assist device support on regional myocardial signal transduction.

Authors:  Keshava Rajagopal; Progyaparamita Saha; Isa Mohammed; Pablo G Sanchez; Tieluo Li; Zhongjun J Wu; Bartley P Griffith
Journal:  J Thorac Cardiovasc Surg       Date:  2015-08-15       Impact factor: 5.209

2.  Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling.

Authors:  Tomoko S Kato; Aalap Chokshi; Parvati Singh; Tuba Khawaja; Faisal Cheema; Hirokazu Akashi; Khurram Shahzad; Shinichi Iwata; Shunichi Homma; Hiroo Takayama; Yoshifumi Naka; Ulrich Jorde; Maryjane Farr; Donna M Mancini; P Christian Schulze
Journal:  Circ Heart Fail       Date:  2011-07-15       Impact factor: 8.790

3.  Expression profile of the matricellular protein osteopontin in primary open-angle glaucoma and the normal human eye.

Authors:  Uttio Roy Chowdhury; Seung-Youn Jea; Dong-Jin Oh; Douglas J Rhee; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-16       Impact factor: 4.799

4.  Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Subha V Raman; Kan N Hor; Wojciech Mazur; Nancy J Halnon; John T Kissel; Xin He; Tam Tran; Suzanne Smart; Beth McCarthy; Michael D Taylor; John L Jefferies; Jill A Rafael-Fortney; Jeovanna Lowe; Sharon L Roble; Linda H Cripe
Journal:  Lancet Neurol       Date:  2014-12-30       Impact factor: 44.182

5.  Osteopontin circulating levels correlate with renal involvement in systemic lupus erythematosus and are lower in ACE inhibitor-treated patients.

Authors:  Marco Quaglia; Annalisa Chiocchetti; Tiziana Cena; Claudio Musetti; Sara Monti; Nausicaa Clemente; Umberto Dianzani; Corrado Magnani; Piero Stratta
Journal:  Clin Rheumatol       Date:  2014-05-13       Impact factor: 2.980

6.  Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension.

Authors:  Adil Anwar; Min Li; Maria G Frid; Binod Kumar; Evgenia V Gerasimovskaya; Suzette R Riddle; B Alexandre McKeon; Roopa Thukaram; Barbara O Meyrick; Mehdi A Fini; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-05-11       Impact factor: 5.464

7.  Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling.

Authors:  Norifumi Takeda; Ichiro Manabe
Journal:  Int J Inflam       Date:  2011-09-18

8.  Genetics of osteopontin in patients with chronic kidney disease: The German Chronic Kidney Disease study.

Authors:  Yurong Cheng; Yong Li; Nora Scherer; Franziska Grundner-Culemann; Terho Lehtimäki; Binisha H Mishra; Olli T Raitakari; Matthias Nauck; Kai-Uwe Eckardt; Peggy Sekula; Ulla T Schultheiss
Journal:  PLoS Genet       Date:  2022-04-06       Impact factor: 5.917

9.  Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans.

Authors:  James Pritchett; Emma Harvey; Varinder Athwal; Andrew Berry; Cliff Rowe; Fiona Oakley; Anna Moles; Derek A Mann; Nicoletta Bobola; Andrew D Sharrocks; Brian J Thomson; Abed M Zaitoun; William L Irving; Indra N Guha; Neil A Hanley; Karen Piper Hanley
Journal:  Hepatology       Date:  2012-09       Impact factor: 17.425

10.  Acetaminophen attenuates doxorubicin-induced cardiac fibrosis via osteopontin and GATA4 regulation: reduction of oxidant levels.

Authors:  Kathryn J Schunke; Luke Coyle; Gary F Merrill; David T Denhardt
Journal:  J Cell Physiol       Date:  2013-10       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.